Compare Flagstar Bank NA (FLG) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Novo Nordisk A/S — how do they compare? Flagstar Bank NA trades at $11.38 (market cap $4.71B), while Novo Nordisk A/S trades at $38.55 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 35.1× Flagstar Bank NA's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and Novo Nordisk A/S for 116 Days on average.
| FLG | NVO | |
|---|---|---|
Market Cap | $4.71B | $165.31B |
Volume | 7,410,589 | 11,432,838 |
Sector | Financials | Health |
52-Week High | $15.36 | $63.98 |
52-Week Low | $10.72 | $35.29 |
Typical Hold Time | 22 Days | 116 Days |
Enterprise Value | $15.25B | $179.56B |
Dividend Yield | 0.35% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Flagstar Bank (FLG) trades at $11.44, up 1.24% with a bearish technical outlook despite recent earnings volatility. The company reported mixed quarterly results with Q2 2026 missing EPS estimates but maintains analyst optimism with a $17.07 consensus target. Fundamentals show improving profitability with net income turning positive in 2026, while valuation metrics present a mixed picture with high P/E but attractive P/B ratio of 0.62.
The stock offers potential upside from current depressed levels given the significant discount to book value and strong analyst buy ratings (60% consensus). Key risks include ongoing earnings volatility, competitive banking pressures, and the challenge of sustaining recent profitability improvements amid economic uncertainty.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
